Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation.
The incidence of recurrent type I membranoproliferative glomerulonephritis (MPGN) after renal transplant is approximately 30%, and the rate of graft loss due to recurrent MPGN type I is higher than 50%. The treatment of this disease has not been defined. We report a case of recurrent MPGN type diagnosed 4 months after a cadaveric renal transplantation. The patient was treated with cyclophosphamide and was able to maintain her graft function. Cyclophosphamide was interrupted three times during the course. Each time her renal function deteriorated and her serum albumin decreased. The patient currently has a functional renal graft 3 years after transplantation while receiving low-dose therapy with cyclophosphamide. We suggest treating recurrent type I MPGN with cyclophosphamide while continuing the calcineurin inhibitor and prednisone.
Lien
Y H
YH
Department of Medicine and Pathology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA.
Scott
K
K
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002102:Cadaver; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone